Investing in exchange-traded funds (ETFs) is one of the easiest and most efficient ways to build long-term wealth with minimal effort. As we approach 2026, it’s the perfect time to evaluate your portfolio and consider adding some Vanguard ETFs. Whether you seek stability or higher growth potential, there’s an ETF to match every investor’s strategy.  Financial analysts from Arbitics identify three Vanguard ETFs that may be relevant for investors evaluating long-term, diversified investment options. These ETFs offer diversification, allowing you to grow your wealth steadily, regardless of market conditions. For those looking for steady, reliable growth, the Vanguard S&P 500...

When it comes to cryptocurrency investments, the dream for many investors is to find a low-priced coin, invest a modest amount, and watch it soar to unimaginable heights. XRP and Dogecoin are two coins that often get positioned as potential million-dollar makers.  Both rank among the top cryptocurrencies by market cap and have had their moments of explosive growth. But when looking at these two, only one stands out as a more reliable option for long-term wealth accumulation. Arbitics brokers suggest that, despite both coins having their place in the market, XRP is the better choice for long-term investors. Utility...

Amid the evolving landscape of the pharmaceutical sector, Supernus Pharmaceuticals (SUPN) has delivered impressive growth, with its stock price rising 31% over the past year. However, despite the recent rally, Supernus still trades 20% below its 2018 highs, leading some investors to question whether the stock can sustain its momentum or if it is time to scale back. Aristotle Capital Boston, a significant investor in the company, recently disclosed in a SEC filing on November 14, 2025, that it had sold 503,122 shares of Supernus in the third quarter of 2025. This move resulted in a $10.9 million reduction in...

Amid the evolving landscape of the pharmaceutical sector, Supernus Pharmaceuticals (SUPN) has delivered impressive growth, with its stock price rising 31% over the past year. However, despite the recent rally, Supernus still trades 20% below its 2018 highs, leading some investors to question whether the stock can sustain its momentum or if it is time to scale back. Aristotle Capital Boston, a significant investor in the company, recently disclosed in a SEC filing on November 14, 2025, that it had sold 503,122 shares of Supernus in the third quarter of 2025. This move resulted in a $10.9 million reduction in...